PROTAC HSP90 degrader BP3

PROTAC HSP90 降解剂 BP3

PROTAC HSP90 degrader BP3

P646332-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN -dependent fashion. PROTAC HSP90 degrader BP3 has a certain certain degradation effect on HSP90 protein in MCF-7 cells ( DC 50 =0.99 µM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell In Vitro PROTAC HSP90 degrader BP3 (compound 16b) (72 h) inhibits the growth of breast cancer cells (IC 50 =0.63 µM in MCF-7 cells, IC 50 =3.53 µM in MDA-MB-231 cells, IC 50 =0.61 µM in 4T1 cells, IC 50 =2.95 µM in MDA-MB-468 cells). PROTAC HSP90 degrader BP3 (2 µM; 6 h) shows degradation activity in the MCF-7 cells (DC 50 =0.99 µM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: MCF-7 cells Concentration: 2 µM Incubation Time: 6 h Result: Showed degradation activity in the MCF-7 cells (DC 50 =0.99 µM). Cell Viability AssayCell Line: 4T1, MDA-MB-468 cells Concentration: 0.01, 1, 100, 10000 µM Incubation Time: 72 h Result: Inhibited the growth of cancer cells (IC 50 =0.61 µM in 4T1 cells, IC 50 =2.95 µM in MDA-MB-468 cells). In Vivo PROTAC HSP90 degrader BP3 (40 mg/kg; i.p., daily for 12 days) inhibits tumor growth and the tumor inhibition rate is 76.41% . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6- to 8-week-old female BALB/c mice Dosage: 40 mg/kg Administration: i.p., daily, 12 days Result: Inhibited tumor growth and the tumor inhibition rate was 76.41%. Form:Solid IC50& Target:HSP90 Cereblon

PROTAC HSP90 降解剂 BP3 能以 CRBN 依赖性方式强效、选择性地降解 HSP90。PROTAC HSP90 降解剂 BP3 对 MCF-7 细胞中的 HSP90 蛋白具有一定的降解作用（DC 50 =0.99 µM）。PROTAC HSP90 降解剂 BP3 可抑制

2669072-88-0

C32H29ClN8O5

641.08 g/mol

O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3NCCC#CC4=CN(CC5=NC=C(C)C(OC)=C5C)C6=NC(N)=NC(Cl)=C64)=O

DMSO : 100 mg/mL (155.99 mM; Need ultrasonic)